Russel J. REITER, FATİH GÜLTEKİN, Luis J. FLORES, M. Pilar TERRON, Dun-Xian TAN

Melatonin: Potential utility for improving public health

Bu derleme melatoninin çeşitli deneysel durum/hastalıktaki faydalı etkilerini özetlemekte ve melatoninin toplum sağlığını geliştirmede faydalı olabilecek kullanım alanlarını belirlemektedir. Melatoninin gecelik kullanımı sıklıkla uyku kalitesini arttırmakta ve “jet lag”la ilişkili sirkadiyan senkronizasyon bozukluğunu düzeltmeye yardımcı olmaktadır. İlave olarak melatoninin çeşitli deneysel kanserlerin büyümesini yavaşlatmada etkili olduğu bulunmuştur. Bu; melatoninin tümör hücreleri tarafından yağ asitlerini, özellikle de linoleik asitin, alımını sınırlamasıyla başarılmaktadır. Yağ asitleri bir çok tümör için büyüme faktörüdür. Buna ilave olarak, melatonin tümör hücrelerinin artmış telomeraz aktivitelerini inhibe etmekte ve dolayısı ile bu hücreleri daha frajil ve kemoterapilere karşı daha duyarlı hale getirmektedir. Melatonin aynı zamanda endotelin-1 üretimini ve hormon-bağımlı tümörlerdeki steroidlerin stimülatuvar etkilerini engelleyen indolü baskılayarak tümörlerdeki anjiogenezisi inhibe edebilir. Eşsiz bir antioksidan olarak melatonin, iskemi/reperfüzyon (I/R) bozukluğunda (kalp krizi) meydana gelen kardiyak hasarı ve beyin I/R bozukluğundaki (inme) beyin hasarını azaltır. Melatonin ayrıca Alzheimer hastalığının iki temel bulgusu olan amiloid  peptid ve nörofibrular düğüm toksititesini sınırlar. Kısacası bu veriler, endojen düzeyleri yaşla azalan, melatonin takviyesinin yaşlılıkta yaşam kalitesini arttırabileceğini ve sonuçta tüm toplum sağlığı için genel olarak faydalı olabileceğini desteklemektedir.

Anahtar Kelimeler:

Antioksidanlar, Melatonin, Halk sağlığı, Serbest radikal süpürücüler, Jet Lag sendromu

Melatonin: Toplum sağlığını geliştirmek için potansiyel kullanımı

This review summarizes the beneficial actions of melatonin in various experimental conditions/diseases and identifies where the use of melatonin may be helpful in improving public health. The nightly use of melatonin supplements by humans often improves their sleep and helps correct the circadian dyssynchronization associated with “jet lag”. Additionally, melatonin has been found effective in curtailing the growth of a variety of experimental cancers. Mechanistically, this is achieved by melatonin’s ability to limit fatty acid uptake, especially linoleic acid, by tumor cells. Fatty acids are growth factors for many tumors. Additionally, melatonin inhibits the elevated telomerase activity of tumor cells thus making them more fragile and vulnerable to chemotherapies. Melatonin also may inhibit angiogenesis in tumors by suppressing endothelin-1 production and the indole interferes with the stimulatory action of steroids on hormone-responsive tumors. As an ubiquitously-acting antioxidant, melatonin reduces cardiac damage during ischemia/reperfusion (I/R) injury (heart attack) and during I/R to the brain (stroke). Melatonin also limits the toxicity of amyloid beta peptide and of neurofibrillary tangles, two of the cardinal signs of Alzheimer’s disease. Collectively, these data suggest supplementation with melatonin, whose endogenous levels decrease with age, may improve the quality of life in the aged and, as a consequence, be beneficial for public health generally.

Keywords:

Antioxidants, Melatonin, Public Health, Free Radical Scavengers, Jet Lag Syndrome,

PDF

___

1. Pappolla MA, Chyan YJ, Poeggeler B, Frangione R, Wilson G et al. An assessment of the antioxidant and antiamyloidogenic properties of melatonin: implications for Alzheimer’s disease. J Neural Transm. 2000; 107:203-31. 2. Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S et al. Effects of melatonin treatment on septic newborns. Pediatr Res. 2001; 50:756-60. 3. Herrera J, Nava M, Romero F, Rodríguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis. 2001; 37:750-7. 4. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Topics Med Chem 2002; 2:113-33. 5. Lissoni P. Is there a role for melatonin in supportive care? Support Care Cancer 2002; 10:110-6. 6. Todisco M, Casaccia P, Rossi N. Severe bleeding symptom’s in refractory idiopathic thrombocytopenia purpura: a case successfully treated with melatonin. Am J Therap. 2003; 10:135-6. 7. Gitto E, Reiter RJ, Cordaro SP, La Rosa M, Chuirazzi P et al. Oxidative and inflammatory parameters in respiratory distress syndrome of preterm infants. Am J Perinotol. 2004; 21:209-16.
8. Reiter RJ, Tan DX, Pappaolla MA. Melatonin relieves the neural oxidative burden that contributes to dementias. Ann NY Acad Sci. 2004; 1035: 179-86. 9. Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, et al. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med. 2005; 6:459-66. 10. Reiter RJ, Tan DX, Leon J, Kilic U, Kilic E. When melatonin gets on your nerves: Its beneficial actions in experimental models of stroke. Exp Biol Med. 2005; 230:104-17. 11. Reiter RJ. The pineal and its hormones in the control of reproduction in mammals. Endocr Rev. 1980; 1:109-31. 12. Lewy AJ. Melatonin as a marker and phase-resetter of circadian rhythms in humans. Adv Exp Med Biol. 1999; 460:425-34. 13. Skinner DC, Malpaux B. High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Golen vein blood recirculating through the choroid plexus. Endocrinology. 1999; 140-4399-405. 14. Reiter RJ. Melatonin: the chemical expression of darkness. Molec Cell Endocrinol. 1991; 79:C153-9. 15. Pang SF, Allen AE. Extra-pineal melatonin in the retina: its regulation and physiological function. Pineal Res Rev. 1986; 4:55-96. 16. Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/melatoninergic system: securing a place under the sun. FASEB J. 2005; 19:176-94. 17. Bubenik GA. Gastrointestinal melatonin: localization, function and clinical relevance. Dig Dis Sci. 2002; 47:2336-48. 18. Conti A, Conconi S, Hertens S, Skwarlo-Sonta K, Markowska M et al. Evidence of melatonin synthesis in mouse and human bone marrow cells. J Pineal Res. 2000; 28:193-202. 19. Carrillo-Vico A, Calvo JR, Abreu P, Lardone PJ, Garcia-Maurino S et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role in intracrine, autocrine, and/or paracrine substance. FASEB J. 2004; 18:537-9. 20. Tan DX, Manchester LC, Hardeland R, Lopez-Burillo S, Mayo JC et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 2003; 34:75-8. 21. Reiter RJ, Richardson BA, Johnson LY, Ferguson BN, Dinh DT. Pineal melatonin rhythm: reduction in aging Syrian hamster. Science 1980; 210:1372-3. 22. Reiter RJ, Craft CM, Johnson JE Jr., King TS, Richardson BA, et al. Age-associated reduction in nocturnal melatonin levels in female rats. Endocrinology. 1981; 109:1295-7. 23. Sack RL, Lewy AJ, Erb DL, Vollmer WM, Singer CM. Human melatonin production decreases with age. J Pineal Res. 1986; 3:479-88. 24. Skene DJ, Vivien-Roels B, Sparks DL, Hunsaker JC, Pevet P et al. Daily variation of the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer’s disease. Brain Res. 1990; 528:170-4. 25. Poeggeler B. Melatonin, aging, and related diseases. Endocrine. 2005; 27:201-12. 26. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. Light suppresses melatonin secretion in humans. Science. 1980; 210:1267-9.
27. Brainard GC, Rollag MD, Hanifin JP. Photic regulation of melatonin in humans: ocular and neural signal transduction. J Biol Rhythms 1997; 12:537-46. 28. Wehr TA. The durations of human melatonin secretion and sleep response to changes in daylength. J Clin Endocrinol Metab. 1991; 73:1276-80. 29. Erren TC, Reiter RJ, Piekarski C. Light, timing of biological rhythms, and chronodisruption in man. Naturwissenschaften 2003; 90:485-95. 30. Brainard GC, Hanifin JP, Greeson JM, Byrne B, Glickman G, et al. Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. J Neurosci. 2001; 21:6405-12. 31. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Dev. 1991; 12:151-80. 32. James SP, Sack DA, Rosenthal NE, Mandelson WB. Melatonin administration in insomnia. Neuropsychopharmacology. 1990; 3:19-23. 33. Oldani A, Ferini-Strambi L, Zacconi M, Stankov B, Fraschini F et al. Melatonin and delayed sleep phase syndrome: ambulatory polygraphic evaluation. Neuroreport. 1994; 30:132-4. 34. Skene DJ, Lockley SW, Arendt J. Use of melatonin in treatment of phase shift and sleep disorders. Adv Exp Med Biol. 1999; 467:79-84. 35. Herxheimer A. Does melatonin help people sleep? BMJ 2006; 332:373-4. 36. Buscerni N, Vandermeer B, Hooton N, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders accompanying sleep restriction: meta-analysis. BMJ doi:10.1136/bmj.38731.532766.F6. 37. Wirz-Justice A, Armstrong SM. Melatonin: nature’s soporific? J Sleep Res. 1996; 5:13-41. 38. Pandi-Perumal SR, Zisapel N, Srinivasan, Cardinali DP. Melatonin and sleep in an aging population. Exp Gerontol. 2005; 40:911-25. 39. Baskett JJ, Broad JB, Word PC, Duncan JR, Pledger MJ, et al. Does melatonin improve sleep in older people? A randomized cross-over trial. Age Ageing. 2003, 32:164-70. 40. Asyama K, Yamadera H, Ito T, Suzaki H, Kudo Y et al. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch. 2003; 70:334-41. 41. Barrett P, Conway S, Morgan PJ. Digging deep-structure-function relationships in the melatonin receptor family. J Pineal Res. 2003, 35:221-30. 42. Arendt J. Jetlag. Lancet. 1998; 351:293-4. 43. Arendt J. Jet-lag and shift work: (2). Therapeutic use of melatonin. J Royal Soc Med. 1999; 92:402-5. 44. Cardinali DP, Brusco LI, Lloret SP, Furio AM. Melatonin in sleep disorders and jet-lag. Neuroendocrinol Lett. 2002; 23 (Suppl.) 1:9-13. 45. Burch JB, Yost MG, Johnson W, Allen E. Melatonin, sleep, and shift work adaptation. J Occup Environ Med. 2005; 47:893-901. 46. Arendt J, Shene DJ. Melatonin as a chronobiotic. Sleep Med Rev. 2005; 9:25-39.
47. Karbownik M, Lewinski A, Reiter RJ. Anticarcinogenic actions of melatonin which involve antioxidative processes: comparison with other antioxidants. Int J Biochem Cell Biol. 2001; 33:735-53. 48. Karbownik M, Reiter RJ, Burkhardt S, Gitto E, Tan DX et al. Melatonin attenuates estradiol-induced oxidative damage to DNA: relation to cancer prevention. Exp Biol Med. 2001; 226:707-12. 49. Reiter RJ. Potential biological consequences of excessive light exposure: melatonin suppression, DNA damage, cancer and neurodegenerative diseases. Neuroendocrinol Lett. 2002; 23 (Suppl 2): 9-13. 50. Vijayalaxmi, Thomas CR Jr, Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol. 2002; 2575-601. 51. Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: The neuroendocrine/circadian melatonin signal. Endocrine. 2005; 27:179-88. 52. Mills F, Wu P, Seely D, Guyott G. Melatonin in the treatment of cancer: a systemic review of randomized trials and meta-analysis. J Pineal Res. 2005; 39:360-6. 53. Sanchez-Barcelo EJ, Cos S, Mediavilla D, Martinez-Campa C, Gonzales A et al. Melatonin-estrogen interactions in breast cancer. J Pineal Res. 2005; 38:217-22. 54. Tamarkin L, Cohen M, Roselle D, Reichert C, Lippman M et al. Melatonin inhibition and pinealectomy enhancement of 7, 12-dimethylbenz (a)anthracene-induced mammary tumors in rats. Cancer Res. 1981; 41 (11 Pt 1):4432-6. 55. Blask DE, Hill SM, Orstead KM, Massa JS Inhibitory effects of the pineal hormone melatonin and underfeeding during the promotional phase of 7, 12-dimethylbenzanthracene (DMBA)-induced mammary carcinogenesis. J Neural Transm. 1986; 67:125-38. 56. Molis TM, Spriggs LL, Jupiter Y, Hill SM. Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer. J Pineal Res. 1995; 18:93-103. 57. Eck KM, Yuan L, Duffy L, Ram PT, Ayettey S, et al. A sequential treatment regimen with melatonin and all-trans retinoic acid induced apoptosis in MCF-7 tumour cells. Br J Cancer. 1998; 77:2129-37. 58. Sainz RM, Mayo JC, Rodríguez C, Tan DX, Lopez-Burillo S et al. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Molec Life Sci. 2003; 60:1407-26. 59. Buyukavci M, Ozdermir O, Buck S, Stout M, Ravindranath Y et al. Melatonin cytotoxicity in human leukemia cells: relation with its pro-oxidant effect. Fundam Clin Pharmacol. 2006; 20:73-9. 60. Jou MJ, Peng TI, Reiter RJ, Jou BS, Wu HY et al. Visualization of the antioxidant effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J Pineal Res. 2004; 37:55-70. 61. Sainz RM, Mayo JC, Tan DX, Lopez-Burillo S, Natarajan M et al. Antioxidant activity of melatonin in Chinese hamster ovarian cells: changes in cellular proliferation and differentiation. Biochem Biophys Res Commun. 2003; 302:625-34. 62. Sauer LA, Dauchy RT, Blask ED. Polyunsaturated fatty acids, melatonin, and cancer prevention. Biochem Pharmacol. 2001; 61:1455-62.
63. Hsi LC, Wilson LC, Eling TE. Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate. J Biol Chem. 2002; 277:40549-56. 64. Blask DE, Sauer LA, Dauchy R, Holowachuk EW, Ruhoff MS. New actions of melatonin on tumor metabolism and growth. Biol Signals Recept. 1999; 8:49-55. 65. Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res. 2005; 65:1174-84. 66. Greider CW, Blackburn EH. Identification of specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 1985; 43:405-13. 67. Bodnar AG, Oullette M, Frolkis M, Hott SF, Chiu CP et al. Extension of life-span by introduction of telomerase into normal cells. Science. 1998; 279:349-52. 68. Counter CM, Avillon AA, LeFeuvre CE, Stewart NG, Greider CW et al. Telomere shortening associated with chromosomal instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992; 11:1921-9. 69. Leon-Blanco M, Guerrero JM, Reiter RJ, Calvo JR, Pozo D. Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J Pineal Res. 2003; 35:204-11. 70. Reiter RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res 2004; 37:213-4. 71. Leon-Blanco MM, Guerrero JM, Reiter RJ, Pozo D. RNA expression of human telomerase subunits TR and TERT is differentially affected by melatonin receptor agonists in the MCF-7 tumor cell line. Cancer Lett. 2004; 216:73-80. 72. Boldrini L, Gisfredi S, Ursino S, Favianna P, Lucchi M, et al. Expression of endothelin-1 is related to poor prognosis in non-small cell lung cancer. Eur J Cancer 2005; 41:2828-35. 73. Knowles J, Loizidou M, Taylor I. Endothelin-1 and angiogenesis in cancer. Curr Vasc Pharmacol 2005; 3:309-14. 74. Kilic E, Kilic U, Reiter RJ, Bassetti CL, Hermann DM. Prophylactic use of melatonin protects against focal cerebral ischemia in mice: role of endothelin converting enzyme-1. J Pineal Res 2004; 37:247-251. 75. Preston-Martin S, Pike MC, ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res. 1990; 50:7415-21. 76. Yager JD. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr. 2000; 27:67-73. 77. Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, et al. Genotoxic metabolites of estrodiol in breast: potencial mechanism of estradiol induced carcinogenesis. J Steroid Biochem Molec Biol. 2003; 86:477-86. 78. Tan DX, Chen LD, Poeggeler B, Manchester LD, Reiter RJ. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993; 1:57-60. 79. Reiter RJ, Tan DX, Manchester LC, Qi W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species. Cell Biochem Biophys. 2001; 34:237-56. 80. Tan DX, Reiter RJ, Manchester LC, Yan MT, El-Sawi M et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Topics Med Chem. 2002; 2:181-97.
81. Allegra M, Reiter RJ, Tan DX, Gentile C, Tesoriere L et al. The chemistry of melatonin’s interaction with reactive species. J Pineal Res. 2003; 34:1-10. 82. Rodríguez C, Mayo JC, Sainz RM, Antolin I, Herrera F et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004; 36:1-9. 83. Tan DX, Poeggeler B, Reiter RJ, Chen LD, Chen S et al. The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole. Cancer Lett. 1993; 70:65-71. 84. Karbownik M, Reiter RJ. Melatonin protects against oxidative stress caused by detal-aminolevulinic acid: implications for cancer reduction. Cancer Invest. 2002; 20:276-86. 85. Reiter RJ. Potential biological consequences of excessive light exposure: melatonin suppression, DNA damage, cancer and neurodegenerative diseases. Neuroendocrinol Lett. 2002; 23 (Suppl 2):9-13. 86. Cos S. Sanchez-Barcelo EJ. Melatonin and mammary pathological growth. Front Neuroendocrinol. 2000; 21:133-70. 87. Sanchez-Barcelo EJ, Cos S, Fernandez R, Mediavilla MD. Melatonin and mammary cancer: a review. Endocr Relat Cancer. 2003; 10:153-9. 88. Cos S, Martinez-Campa C, Mediavilla MD, Sanchez-Barcelo EJ. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res 2005; 38:136-42. 89. Landeghem AA, Poortman J, Nabuurs M, Thijssen JG. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 1985; 45:2900-6. 90. Harada N. Aberrant expression of aromatase in breast cancer tissues. J Steroid Biochem Molec Biol. 1997; 61:175-84. 91. Yue W, Wang JP, Hamilton CJ, Dem ers L, Santen RJ. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res. 1998; 58:927-32. 92. Hardeland R, Balzer I, Poeggeler B, Fuhrbert B, Uria H et al. On the primary functions of melatonin in evolution: mediation of photoperiodic signals in a unicells, photooxidation, and scavenging of free radicals. J Pineal Res. 1995; 18:104-11 93. Poeggeler B, Thuermann S, Dose A, Schoenke M, Burkhardt S et al. Melatonin’s unique radical scavenging properties – roles of its functional substituents as revealed by a comparison with its structural analogues. J Pineal Res. 2002; 33:20-30. 94. Reiter RJ, Tan DX, Manchester LC, Lopez-Burillo S, Sainz RM et al. Melatonin: detoxification of oxygen and nitrogen-based toxic reactants. Adv Exp Med Biol. 2004; 59:539-48. 95. Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Progr Neurobiol. 1998; 56:359-84. 96. Mayo JC, Rosa RM, Tan DX, Antolin I, Rodriquez C et al, Melatonin and Parkinson’s disease. Endocrine. 2005; 27:169-178. 97. Nishida, S. Metabolic effects of melatonin on oxidative stress and diabetes mellitus. Endocrine. 2005; 27:131-136. 98. Halliwell B. Antioxidants and human disease: a general introduction. Nutr Rev. 1997; 55 (1 Pt 2): S44-52.
99. Poeggler B, Reiter RJ, Tan DX, Chen LD, Manchester LC. Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. J Pineal Res. 1993; 14:151-68. 100. Harman D. Aging and oxidative stress. J Int Fed Clin Chem. 1998; 10:24-7. 101. Reiter RJ, Guerrero JM, Garcia JJ, Acuna-Castroviejo D. Reactive oxygen intermediates, molecular damage, and aging: relation to melatonin. Ann NY Acad Sci. 1998; 854:410-24. 102. Harman D. Aging: overview. Ann NY Acad Sci. 2001; 928:1-21. 103. Wu YH, Swaab D. The human pineal gland and melatonin in aging and Alzheimer’s disease. J Pineal Res 2005; 38:145-152. 104. Reiter RJ, Tan DX, Maldonado M. Melatonin as an antioxidant: physiology versus pharmacology. J Pineal Res. 2005; 39:215-16. 105. Tan DX, Manchester LC, Sainz RM, Mayo JC, Leon J et al. Physiological ischemia/reperfusion phenomena and their relation to endogenous melatonin production: an hypothesis. Endocrine. 2005; 21:149-57. 106. Reiter RJ, Tan DX, Kim SJ, Qi W. Melatonin as a pharmacological agent against oxidative damage to lipids and DNA. Proc West Pharmacol Soc. 1998; 41:229-36. 107. Chen YH, Xu DX, Wang JP, Wang H, Wei LZ et al. Melatonin protects against lipopolysaccharide-induced intra-uterine fetal death and growth retardation in mice. J Pineal Res. 2006; 40:40-7. 108. Petrosillo G, Di Venosa N, Pistolese M, Casanova G, Tiravanti E et al. Protective effective of melatonin against mitochondrial dysfunction associated with cardiac ischemia-reperfusion: role of cardiolipin. FASEB J. 2006; 20:269-79. 109. Reiter RJ, Tan DX, Kim SJ, Manchester LC, Qi W et al. Augmentation of indices of oxidative damage in life-long melatonin-deficient rats. Mech Aging Dev. 1999; 110:157-73. 110. Tesoriere L, D’Arpa D, Conti S, Pintaudi AM, Livera MA. Melatonin protects human red blood cells from oxidative hemolysis: new insights into the radical scavenging activity. J Pineal Res. 1999; 27:95-105. 111. Okatani Y, Wakatsuki A, Reiter RJ, Miyahara Y. Melatonin reduces oxidative damage of neural lipids and proteins in senescence-accelerated mouse. Neurobiol Aging. 2002; 23:639-44. 112. Pappolla MA, Chyan YJ, Poeggeler B, Bozner P, Ghiso J et al. Alzheimer’s beta protein mediated oxidative damage of mitochondrial DNA: prevention by melatonin. J Pineal Res. 1999; 27:226-9. 113. Bozner P, Grishko V, La Daux SP, Wilson GL, Chyan Y et al. The amyloid beta protein induces oxidative damage of mitochondrial DNA. J Neuropathol Exp Neurol. 1997; 56:1356-62. 114. Onuki J, Almeida EA, Medeiros MH, Di Mascio P. Inhibition of 5-aminolevulinic acid-induced DNA damage by melatonin, N1-acetyl-N2-formyl-5-methoxykynuramine, quercetin or resveratrol. J Pineal Res. 2005; 38:107-15. 115. Vijayalaxmi, Reiter RJ, Tan DX, Herman TS, Thomas CR Jr. Melatonin as a radioprotective agent. Int J Radiat Oncol Biol Phys. 2004; 59:639-53.
116. Benot S, Molinero P, Soutto M, Goberna R, Guerrero JM. Circadian variations in the rat serum total antioxidant status: Correlation with melatonin levels. J Pineal Res. 1998; 25:1-4. 117. Benot S, Gobena R, Reiter RJ, Garcia-Maurino S, Osuna C et al. Physiological levels of melatonin contribute to the antioxidant capacity of human serum. J Pineal Res. 1999; 27:59-64. 118. Reiter RJ, Manchester LC, Tan DX. Melatonin in walnuts: influence on levels of melatonin and total antioxidant status of blood. Nutrition. 2005; 21:920-4. 119. Tan DX, Chen LD, Poeggeler G, Manchester LC, Reiter RJ. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993; 1:57-60. 120. Reiter RJ, Tan DX, Gitto E, Sainz RM, Mayo JC et al. Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage. Pol J Pharmacol. 2004; 56:159-170. 121. Hardeland R. Antioxidative protection by melatonin. Endocrine. 2005; 27:119-30. 122. Tan DX, Manchester LC, Sainz RM, Mayo JC, Leon J et al. Interactions between melatonin and nicotinamide nucleotide: NADH preservation in cells and in cell-free systems by melatonin. J Pineal Res. 2005; 39:185-94. 123. Tan DX, Manchester LC, Burkhardt S, Sainz RM, Mayo JC et al. N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J. 2001; 15:2294-6. 124. de Almeida EA, Martinez GR, Klitzke CF, de Medeiros MH, Di Mascio P. Oxidation by melatonin by singlet oxygen produces N1-acetyl-N2-formyl-5-methoxykynuramine. J Pineal Res. 2003; 35:131-7. 125. Ressmeyer AR, Mayo JC, Zelosko V, Sainz RM, Tan DX et al. Antioxidant properties of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK) scavenging of free radicals and prevention of protein destruction. Redox Rep. 2003; 8:205-13. 126. Silva SO, Rodrigues MR, Carvalho SR, Catalaui LH, Campa A et al. Oxidation of melatonin and its catabolites, N1-acetyl-N2-formyl-5-methoxykynuramine and N-acetyl-5-methoxykynuramine, by activated leukocytes. J Pineal Res 2004; 37:171-5. 127. Antolin I, Rodriguez C, Sainz RM, Mayo JC, Uria H et al. Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes. FASEB J 1996; 10:882-90. 128. Rodríguez C, Mayo JC, Sainz RM, Antolin I, Herrera F et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004; 36:1-9. 129. Tomas-Zapico C, Coto-Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res. 2005; 39:99-104. 130. Urata Y, Honma S, Goto S, Todoroki S, Iida T et al. Melatonin induces gamma-glutamylcysteine synthase mediated by activator protein-1 in human vascular endotelial cells. Free Radic Biol Med. 1999; 27:838-47. 131. Winiarska K, Fraczyls T, Malinska D, Drozak J, Bryla J. Melatonin attenuates diabetes-induced oxidative stress in rabbits. J Pineal Res. 2006; 40:168-76.
132. Acuña-Castroviejo A. Escames G, Carazo A, Leon J, Khaldy H et al. Melatonin, mitochondrial homeostasis and mitochondrial related diseases. Curr Top Med chem. 2002; 2:133-51 133. Leon J, Acuna-Castroviejo D, Escames G, Dan DX, Reiter RJ. Melatonin mitigates mitochondrial malfunction. J Pineal Res. 2005; 38:1-9. 134. Tan DX, Manchester LC, Reiter RJ, Qi W, Kim SJ et al. Ischemia/reperfusion-induced arrhythmias in the isolated rat heart: prevention by melatonin. J Pineal Res. 1998; 25:184-91. 135. Dave RH, Hale SL, Kloner RA. The effect of melatonin on hemodynamics, blood flow, and myocardial infarct size in a rabbit model of ischemia-reperfusion. J Cardiovasc Pharmacol Therap. 1998; 3:153-60. 136. Lagneux C, Joyeux M, Demenge P, Ribuot C, Godin-Ribuot D. Protective effects of melatonin against ischemia-reperfusion injury in the isolated rat heart. Life Sci. 2000; 66:503-9. 137. Dobsak P, Siegelova J, Eicher JC, Jancik J, Svacinova H et al. Melatonin protects against ischemia-reperfusion injury and inhibits apoptosis in isolated working rat heart. Pathophysiology. 2003; 9:179-87. 138. Reiter RJ, Tan DX. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. J Cardovasc Res. 2003; 58:10-9. 139. Lochner A, Genade S, Davids A, Ytrebus K, Moolman JA. Short- and long-term effects of melatonin on myocardial post ischemic recovery. J Pineal Res. 2006; 20:269-76. 140. Wakatsuki A, Okatani Y, Izumiya C, Ikenove M. Melatonin protects against ischemia and reperfusion-induced oxidative lipid and DNA damage in fetal rat brain. J Pineal Res. 1999; 26:147-52. 141. Borlongan CV, Yamamoto M, Takei N, Kumazaki M, Ungsuparkorn C et al. Gial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia. FASEB J. 2000; 17:1307-17. 142. Cuzzocrea S, Costantino G, Gitto E, Mazzon E, Fulia F et al. Protective effects of melatonin in ischemic brain injury. J Pineal Res. 2000; 29:217-27. 143. Pei Z, Ho HT, Cheung RT. Pre-treatment with melatonin reduces volume of cerebral infarction in a permanent middle cerebral artery occlusion stroke model in the rat. Neurosci Lett. 2002; 318:141-4. 144. Cheung RT. The utility of melatonin in reducing cerebral damage resulting from ischemia and reperfusion. J Pineal Res 2003; 34:153-60. 145. Kilic E, Kilic U, Yulug B, Hermann DM, Reiter RJ. Melatonin reduces disseminate neuronal death after mild focal ischemia in mice via inhibition of caspase-3 and its suitable as an add-on treatment to tissue-plasminogen activator. J Pineal Res. 2004; 36:171-6. 146. Gupta S, Kaul CL, Sharma SS Neuroprotective effect of combination of poly (ADF ribose) polymerase inhibitor and antioxidant in middle cerebral artery occlusion induced focal ischemia in rat. Neurol Res. 2004; 26:103-7. 147. Torii K, Uneyama H, Nishino H, Dondoh T. Melatonin suppresses cerebral edema caused by middle cerebral artery occlusion/reperfusion in rats assessed by magnetic resonance imaging. J Pineal Res. 2004; 36:18-24.
148. Lee EJ, Lee MY, Chen HY, Hsu YS, Wu TS et al. Melatonin attenuates gray and white matter damage in mouse model of transient focal cerebral ischemia. J Pineal Res. 2005; 38:42-53. 149. Guerrero JM, Reiter RJ, Ortiz GG, Pablos MI, Sewerynek E et al. Melatonin prevents increases in neural nitric oxide and cyclic GMP production after transient brain ischemia and reperfusion in the Mongolian gerbil (Meriones unguiculatus). J Pineal Res. 1997; 23:24-31. 150. El-Abhar HS, Shaalan M, Barakat M, El-Denshary ES. Effect of melatonin nifedipine on some antioxidant enzymes and different energy fuels in the blood and brain of global ischemic rats. J Pineal Res 2002; 33:87-94. 151. Reiter RJ, Sainz RM, Lopez-Burillo S, Mayo JC, Manchester LC et al. Melatonin ameliorates neurologic damage and neurophysiologic deficits in experimental models of stroke. Ann NY Acad Aci. 2003; 993:35-47. 152. Yamaguchi H. Illustration of dynamic changes in Alzheimer pathology: from mild impairment to terminal stage. Neuropathology. 2005; 25:285-7. 153. Polick J, Corey-Bloom J. Alzheimer’s disease and P300: review and evaluation of task and modality. Curr Alzheimer Res. 2005; 2:515-25. 154. Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002; 298:789-91. 155. Echert A, Keil U, Marques CA, Bonest A, Frey C et al. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer’s disease. Biochem Pharmacol. 2003; 66:1627-34. 156. Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer’s and Parkinson’s diseases. Nat Cell Biol. 2004; 6:1054-61. 157. Saragoni L, Hernandez P, Maccioni BB. Differential association of tau with subsets of microtubles containing posttranslationally-modified tubulin variants in neuroblastoma cells. Neurochem Res. 2000; 25:59-70. 158. Billingsley ML, Kincaid JJ. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intraction, intracellular trafficking and neurodegeneration. Biochem J. 1997; 323)577-91. 159. Braak E, Braak H, Mendelkow EM. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neutrophil threads. Acta Neuropathol. 1994; 87:554-67. 160. Selkoe DJ. The cell biology beta-amyloid precursor protein and presenilins in Alzheimer’s disease. Trends Cell Biol. 1998; 8:447-53. 161. Song W, Lahiri DK. Melatonin alters the metabolism of the beta-amyloid precursor protein in the neuroendocrine cell line PC12. J Mol Neurosci, 1997; 9:75-92. 162. Zhang YC, Wang ZF, Wang Q, Wang YP, Wang JZ. Melatonin attenuates overproduction of ?-amyloid-induced inhibition in expression of neurofilament protein. Acta Pharmacol Sinica. 2004; 25:447-51. 163. Matsubara E, Bayant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic Mouse model of Alzheimer’s disease. J Neurochem. 2003; 85:1101-8.
164. Quinn J, Kulhanek D, Nowlin J, Jones R, Pratico D et al. Chronic melatonin therapy fails to alter the amyloid burden or oxidative damage in old Tg 2576 mice: implications for clinical trials. Brain Res. 2005; 1037:209-13. 165. Poeggeler G, Miranalle L, Zagorski MG, Wisniewski T, Chyan YJ et al. Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide. Biochemistry. 2001; 40:14995-5001. 166. Pappolla MA, Bozner P, Soto C, Shao H, Robakis NK et al. Inhibition of Alzheimer ?-fibrillogenesis by melatonin. J Biol Chem 1998; 273:7185-8. 167. Pacchierottio C, Iapichino P, Bossini L, Pieraccini F, Castrogiovanni P. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front Neuroendocrinol. 2001; 22:18-32. 168. Shen YX, Xu SY, Wei W, Sun XX, Liu LH et al. The protective effects of melatonin from oxidative damage induced by amyloid beta-peptide 25-35 in middle-aged rats. J Pineal Res. 2002; 32:85-9. 169. Rosales-Corral S, Tan DX, Reiter RJ, Valdivia-Velazquez M, Martinez-Barbosa G et al. Orally administered melatonin reduces oxidative stress and proinflammatory cytokines induced by amyloid?-peptide in rat brain: a comparative in vivo study versus vitamin C and E. J Pineal Res. 2003; 35:80-4. 170. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K. Post-translation modifications of tau protein in Alzheimer’s disease. J Neural Transm. 2005; 112:813-38. 171. Deng YQ, Xu GG, Duan P, Zhang Q, Wang JZ. Effects of melatonin on wortmannin-induced tau hyperphosphorylation. Acta Pharmacol Sinica. 2005; 26:519-26. 172. Li SP, Deng YQ, Wang XC, Wang YP, Wang JZ. Melatonin protects SH-SY5Y neuroblastoma cells from calyculin A-induced neurofilament impairment and neurotoxicity. J Pineal Res. 2004; 36:186-91. 173. Wang YP, Li XT, Liu SJ, Wang YP, Wang JZ. Melatonin ameliorates okadaic acid-induced Alzheimer-like lesions. Acta Pharmacol Sinica. 2004; 25:276-80. 174. Liu SJ, Wang JZ. Alzheimer-like tau hyperphosphorylation induced by wortmannin in vivo and its attenuation by melatonin. Acta Pharmacol Sinica. 2002; 23:183-7. 175. Wang DL, Ling ZQ, Cao FY, Shu LQ, Wang JZ. Melatonin attenuates isoproterenol-induced protein kinase A overactivation and tau hyperphosphorylation in rat brain. J Pineal Res. 2004; 37:11-6. 176. Avila J. Tau aggregation into fibrillar polymers: taupathies. FEBS Lett. 2000; 476:82-92. 177. Benitz-King G. Melatonin as a cytoskeleton modulator: implications for cell physiology and disease. J Pineal Res. 2006; 40:1-9.